Correlation of 6-Minute Walk Test (6MWT) with Spirometric Findings in Patients of COPD

Satish Chandra

ABSTRACT

Introduction: Chronic Obstructive Pulmonary Disease (COPD) is a major health problem globally. Spirometry is the Gold standard for the diagnosis of COPD and it also grades its severity. 6MWT is a simple reproducible test to assess the patient’s functional capacity. It is of help in management and prediction of prognosis. Objective: This study was done to find correlation between 6MWT results with patient’s clinical and spirometric parameters. The study also assessed if 6 minute walk distance (6MWD) can be an alternative to spirometry in predicting severity of COPD in resource poor setup.

Material and methods: This was a hospital based cross sectional study. 60 consecutive confirmed patients of COPD (by GOLD guidelines) were included in the study after applying inclusion and exclusion criteria. Severity was assessed by pre and post-bronchodilator spirometry test. This was followed by 6MWT as per ATS guidelines. 6MWD was recorded and % predicted 6MWD was also calculated. Results of 6MWT were correlated with spirometric and clinical parameters of the patients.

Results: 6MWD had statistically significant (p <.05) positive correlation with following parameters: Height, FEV1, % predicted FEV1, FVC, FEV1/FVC and PEFR. Correlation with age, weight and BMI was not significant. % 6MWD significantly correlated with Height, FEV1, % predicted FEV1, FVC and PEFR. Distances in meters walked by different severity groups were as follows: Mild: 410 ± 15; Moderate: 367.66 ± 57.71; Severe: 364.60 ± 62.91 and Very severe: 281.21 ± 55.99. On one way analysis of variance (ANOVA) these differences were found significant (p <.01)

Conclusion: In this study 6MWD and percent 6MWD had significant positive correlation with patients’ parameters (Height, FEV1, %FEV1, FVC and PEFR). The severity of COPD may be assessed with 6MWT.

Keywords: Chronic Obstructive Pulmonary Disease, Spirometry, 6 - Minute Walk Test

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a major cause of death and debility globally. It is an irreversible disease characterized by airflow limitation. Spirometry is the Gold standard for the diagnosis of COPD. This test also grades the severity of the disease which helps in the management.1

Many times Spirometry is not available in remote areas. In these situations 6MWT can be done. 6 minute walk test (6MWT) is a simple test to assess patient’s functional capacity (ability for day to day activities). The test is reproducible and cost effective requiring minimal equipment.2-4 Some studies have found results of 6MWT to be more reproducible than measurement of FEV1.5,6 In 2002 ATS approved 6MWT as standard test for assessment of pulmonary function. In COPD the patient’s lung function deteriorates and disability increases with age. Improvement in patient’s symptoms is an important goal in the management of COPD. The management is guided by the severity of airways limitation (GOLD stages). The spirometric results (FEV1) may or may not give true picture of patient’s exercise capacity. It is important to know whether severity stages based on GOLD guideline correlate with functional capacity of patient. 4 In this context it is worthwhile to know if the flow and volume indices of spirometry correlate with the result of 6MWT. There are not many published articles in India correlating the severity of COPD (based on FEV1) and the exercise capacity of the patient. The present study was done to correlate the spirometric data with result of 6MWT and assess whether 6MWT can be an alternative to spirometry in predicting the disease severity of COPD.

MATERIAL AND METHODS

This was a cross sectional study conducted in the Department of T.B. & Chest, Nalanda Medical College and Hospital, Patna from October 2019 to January 2020. The project was approved by the Ethics committee of the institution. Consent of the patients was obtained and consecutive patients were selected from among the confirmed cases of COPD (clinical features and GOLD criteria) coming to the T.B. & Chest out-patient door. The patients were included in the test after applying following inclusion and exclusion criteria:

Inclusion criteria:
• All confirmed cases of COPD
• Age >25 years

Exclusion criteria: Patients of confirmed COPD but having contraindications as below:
• HR >120/mt
• BP > 180/100
• Evidence of LVF, IHD, other major CV diseases
• Neurological diseases of lower limbs

1Associate Professor and H.O.D., Department of T.B. & Chest, Nalanda Medical College, Patna, India

Corresponding author: Dr. Satish Chandra, Road No 2, Rajendra Nagar, South of Kishor Dal School, Patna 800016 (Bihar), India

How to cite this article: Satish Chandra. Correlation of 6-minute walk test (6MWT) with spirometric findings in patients of COPD. International Journal of Contemporary Medical Research 2020;7(4):D4-D7.

DOI: http://dx.doi.org/10.21276/ijcmr.2020.7.4.10
Spirometry: It was performed by an experienced technician and as per guideline of American Thoracic Society. The best result of three attempts were selected for analysis. Spirometry was repeated 15 minutes after administration of short acting bronchodilator. Spirometric indices FEV1, %FEV1, FVC, FEV1/FVC ratio and PEFR were recorded. Patients showing obstructive ventilatory defect were grouped as mild, moderate and severe and very severe as per GOLD guidelines.

6MWT: Within one hour of spirometry, 6MWT was done on a 30 meter stretch (according to the ATS guideline) as follows:
- Patient were rested 10 minutes prior to the test.
- Baseline heart rate (HR), Blood pressure (BP), SpO2 and dyspnea status were recorded. These parameters were again recorded at the end of the test.
- Distance walked in 6 minutes was recorded in meters.
- The test was discontinued if any of the following occurred: chest pain, severe dyspnea, spasm of lower extremity muscles or if the patient wanted to quit.
- Post-test the patients were be observed for 15 minutes for any adverse events.

Percent (%) 6MWD
This was calculated from published reference equations for Indian population. The following equations were used:
Predicted 6MWD (For males) = 561.022 - (2.507 × age [years]) + (1.505 × weight [kg]) - (0.055 × height [cm]);
and predicted 6MWD (for females) = 30.325 – (0.809 x age [years]) - (2.074xweight [kg]) + (4.235 x height [cm])

Other tests and information:
They included routine haematological tests and Chest X-ray. The patients’ demographic data (age, sex, religion, socio-economic status, occupation, and smoking habit) was also recorded.

STTATISTICAL ANALYSIS
Statistical analysis of the compiled data was done. The correlation was evaluated using Pearson’s correlation coefficient ‘r’. One way analysis of variance (ANOVA) was done to study significance of variation in 6MWD in different severity groups of COPD. The criteria for significant was set at p <.05 and very significant at p <.001. (Statistical calculation were done with software available at website: socscistatistics.com and Microsoft Word Excel 2013 sheet).

RESULTS
The study population included 60 patients. Among them 36 (60%) were males and 24 (40%) were females. According to age the patients were grouped in five age groups: 25-35, >35 -45, >45 -55, >55 -65 and above 65 years. 23 patients (38.3%) belonged to age group >45 -55 years and 14 patients (23.3%) belonged to age group >55 -65. (Table 1)

Table 2 shows the no. of patients in different severity groups (GOLD stages). 3 patients (5%) were in stage I, 21 patients (35%) were in stage II, 29 patients (48.3%) were in stage III and 7 patients (11.7%) were in stage IV disease. Statistical analysis of patients demographic characters, spirometric and 6MWT data was done. These have been summarized in Table 3. The mean and standard deviation of demographic parameters are as follows: Age: 50.68 ± 11.31; Height (cms): 154.96 ± 08.96; Weight (Kg): 44.85±11.06; BMI: 18.67±4.43. Spirometric and 6MWT parameters had the following mean and standard deviation: PEFR (liters/sec): 2.10±1.08; FEV1 (liters): 1.04±0.48; FEV1 (% predicted): 48.16±18.24; FVC (liters):1.81±0.70; FEV1/ FVC: 55.13±10.79; 6MWD (meters):358.21±65.0; %
significant correlation with age, weight and BMI was found. Distances in meters walked by different severity groups were as follows: Mild: 410 ± 15; Moderate: 367.66 ± 57.71; Severe: 364.60 ± 62.91 and Very severe: 281.21 ± 55.99. (Table-5). The differences in 6MWD of different severity groups were significant in ANOVA test. (F ratio: 4.99; p <.01).

**DISCUSSION**

Assessment of disease severity is important in the management of COPD. Presently severity is assessed by post-bronchodilator FEV1 (%predicted) as per GOLD guidelines. 6MWT can be a helpful tool in assessing severity of disease where spirometry is not available. The present study showed significant correlation of 6MWD and % 6MWD with spirometric and clinical indices (PEFR, FEV1, %FEV1, FVC and height).

**Correlation with 6MWD (Table 4, Figures 1 and 2)**

PEFR: This study showed that PEFR had significant positive correlation with 6MWD (r = 0.5565, p <.0001). These findings are in conformity with other studies which demonstrated similar correlation between PEFR and 6MWD.9-11 Some of the authors reported correlation between %PEFR and 6MWD.9-11 FEV1: The present study showed moderate but significant positive correlation between FEV1 and 6MWD (r = 0.5147, p <.0001). Various previous studies have also observed similar strong correlation between FEV1 and 6MWD.2,9,10,12,13 The result of this study contradicted the reports of Kodawala et al and Patel A which did not find significant correlation between 6MWD and FEV1.14,15 % FEV1: significant correlation between % FEV1 and 6MWD (r = 0.381, p <.01) was observed in present study. Various previous studies have also found similar correlation between FEV1 and 6MWD.9,10,11,16 One study by Chauhan et al did not find any such correlation.17 FVC: Current study showed significant positive correlation between FVC and 6MWD (r = 0.4488, p <.0001). Other studies too reported similar results of correlation between 6MWD and FVC.9,10,12,15,16 Three studies found correlation with % FVC also.9,10,16 One study by Kodawala et al found no such correlation.14 FEV1/FVC: In this study significant correlation was found between FEV1/FVC ratio and 6MWD (r = 0.357, p <.01). Some of the studies have reported similar results.9-12 But Kundu et al and Nagshin et al did not find any correlation between 6MWD and FEV1/FVC ratio.2,10

### Table-5: Significance of difference in 6 M W D among patients in different severity stages: ANOVA test

| Gold stage | FEV1 | No. of patients (n=60) | 6 minute walk distance (Mean ± SD) |
|------------|------|------------------------|-----------------------------------|
| I          | >80% | 03                     | 410 ± 15                           |
| II         | ≥50 - <80% | 21 | 367.66 ± 57.71             |
| III        | ≥30 - <50% | 29 | 364.60 ± 62.91             |
| IV         | <30% | 07 | 281.21 ± 55.99             |
| F ratio: 4.99, p value: <.01 |

Table 4 shows correlation of 6MWD and % predicted 6MWD with parameters of patient. There was significant positive correlation of 6MWD and % predicted 6MWD with height and spirometric parameters PEFR, FEV1, % predicted FEV1, FVC. 6MWD also significantly correlated with FEV1/FVC. However no
Height, Weight and BMI: Present study showed significant correlation between height and 6MWD. Another study also found significant correlation with height. 9 Correlation with weight and BMI was not significant in present study. Kumar et al reported correlation between 6MWD and weight, BMI, but no correlation with height. 9 While others did not find correlation between 6MWD and BMI.2,11,12,14

Correlation with % 6MWD
The current study also found significant correlation between % 6MWD and Height, PEF, FEV1, %FEV1, FVC. [Table 4] A previous study found correlation between % 6MWD and BMI, %FEV1, FEV1/FVC. 7 Yet another study demonstrated significant correlation with FEV1 and FVC but no correlation with FEV1/FVC. 9

Analysis of variance
The differences in the 6 minute walk distances of different severity groups was evaluated with ANOVA test and found to be significant (F ratio:4.99; p < .01) (Table 5) There are certain limitations of our study. There was no control group of healthy people. The test was done after a post-bronchodilator spirometry. This could have improved the walk distance. Repeat test was not done to assess reproducibility.

CONCLUSION
The present study identified significant correlation of 6MWD with spirometric parameters PEF, FEV1, %FEV1, FVC, FEV1/FVC and height. This suggests that in the absence of spirometry 6MWT is a reasonable tool for the assessment of disease status in COPD.

ACKNOWLEDGEMENTS
The author is thankful to the staff of Department of T.B. & Chest, Nalanda Medical College, Patna for their cooperation in this research work.

REFERENCES
1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (Revised 2016). http://www.goldcopd.org.
2. Kundu A, Maji A, Sarkar S, Saha K, Jash D, Maikap M. Correlation of six minute walk test with spirometric indices in chronic obstructive pulmonary disease patients: A tertiary care hospital experience. J Asso Chest Physicians 2015;3:9-13.
3. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
4. Agrawal SR, Joshi R, Jain A. Correlation of severity of chronic obstructive pulmonary disease with health related quality of life and six-minute walk test in a rural hospital of central India. Lung India 2015;32:233-40.
5. Wijkstra PJ, Ten Vergert EM, Vander Mark Th W et al. Relation of lung function, maximal inspiratory pressure, dyspnea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. Thorax 1994;49:468-72
6. Knox AJ, Morrison JF, Muers MF. Reproducibility of walking test results in chronic obstructive airways disease. Thorax 1988;43:388
7. Miller MR, Hankinson J, Brusasco V. et al. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
8. Ramnathan RP, Chandrasekharan B. Reference equations for 6-min walk test in healthy Indian subjects (25-80) years. Lung India 2014;31:35-8
9. Khandelwal MK, Maheshwari VD, Garg S, Kumar K, Gupta R, Khandelwal S. “Six minute walk distance: correlation with spirometric & clinical parameters in chronic obstructive pulmonary disease.” International J of Healthcare and Biomedical Research, Volume 1; Issue 3, April 2013, pages 217-226
10. Nagshrin R, Zaker MM, Afsar AE. Association between Six-Minute Walk Test and Expiratory Spirometry Parameters in Chronic Obstructive Pulmonary Disease. (Iranian heart Journal 2005;6:59-63)
11. Tamakhuwala G, Shamaliya K, Patel M, Patel B. A study of correlation of 6 Minutes Walk Test & Spirometry findings in COPD patients. Int J Res Med. 2017;612-20
12. Al Ameri HF. Six minute walk test in respiratory diseases: A university hospital experience. Ann Thorac Med 2006;1:16-9
13. Chulmsky J, Sterbova L, Smolikova L, Matous M, Salajka F: Relation between pulmonary ventilation parameters, exercise tolerance and quality of life in patients with chronic obstructive lung diseases; vnitr lek; 2002;48:320-324
14. Kodawala A K, Dash S. Correlation between Forced Expiratory Volume in First Second (FEV1) And 6 Minute Walk distance In Moderate, Severe and Very Severe Chronic Obstructive Pulmonary Disease. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) 2013;5:72-76
15. Patel A. European Respiratory Journal 2015; 46: PA604.
16. Bavarsad M B, Eldani E, Shariati A and Latifi M. Relationship Between Exercise Capacity and Clinical Measures in Patients with Chronic Obstructive Pulmonary Disease. Biomed. & Pharmacol. J 2015;8:01-07.
17. Chauhan N K. Correlation between FEV1 Percentage and 6 Minute Walk Distance in Patients of Chronic Obstructive Pulmonary Disease. Indian J Physiol Pharmacol 2017; 61:38-4
18. Aggrawal M B and Awad N T. Correlation between 6 Minute Walk distance In Moderate, Severe and Very Severe Chronic Obstructive Pulmonary Disease. IOSR Journal of Clinical and Diagnostic Research. 2015;9:OC01-OC04.

Source of Support: Nil; Conflict of Interest: None
Submitted: 28-02-2020; Accepted: 16-03-2020; Published: 14-04-2020